Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sleep and Healthy Aging Research on Depression for Younger Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03848715
Recruitment Status : Recruiting
First Posted : February 21, 2019
Last Update Posted : November 3, 2020
Sponsor:
Information provided by (Responsible Party):
Chloe Boyle, PhD, University of California, Los Angeles

Brief Summary:
Compelling evidence indicates inflammation plays a role in depression, but potential mechanisms linking inflammation to depression, such as dysregulated reward processing, are poorly understood. This study comprehensively evaluates effects of inflammation on reward across dimensions (e.g., anticipating versus receiving a reward) and types (e.g., money vs. smiling faces) in younger and older women. Characterizing how inflammation shapes the dynamic and multidimensional reward system, and how this may differ by age, may give insight into risk factors for depression and help identify critical points for intervention.

Condition or disease Intervention/treatment Phase
Anhedonia Depression Biological: Endotoxin Biological: Placebo Phase 1

Detailed Description:
This study will use an inflammatory challenge (i.e., endotoxin) to assess effects of inflammation on the behavioral response to social and non-social rewards, using tasks that assess reward motivation, sensitivity, and learning. Both elevated inflammation and reward dysregulation are associated with depression and have been shown to predict depression onset; understanding how inflammation alters the reward system in the laboratory setting may provide insight into risk factors and help identify potential areas for intervention. In this placebo-controlled, randomized, double-blind study of low dose endotoxin in 40 adult premenopausal women (25-44 y), the investigators will examine effects of endotoxin on reward responsiveness across dimensions (i.e., motivation, sensitivity, learning) and reward types (e.g., social and non-social). The investigators hypothesize that as compared to placebo, endotoxin will 1) decrease non-social reward responses across reward dimensions; 2) decrease "general" social reward responses across reward dimensions; 3) increase "close" social reward responses across reward dimensions; 4) decrease resting eye blink rate (EBR); EBR will be correlated with learning and motivation for non-social reward. The second component of the study is to examine whether effects of endotoxin on reward differ as a function of age; in particular it is hypothesized that effects will be more robust in younger compared to older women. In order to test for age differences, this study will use data from 40 older women (65+ y) participating in a parallel ongoing randomized controlled trial (ClinicalTrials.gov Identifier: NCT03256760). Thus, the investigation aims to: 1) Evaluate effects of inflammation on non-social reward as a function of age; 2) Evaluate effects of inflammation on general and close social reward as a function of age; 3) Examine changes in dopaminergic activity as a mechanism linking effects of inflammation on non-social reward processing as a function of age.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Endotoxin vs Placebo
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: Blinded infusion
Primary Purpose: Other
Official Title: Sleep and Healthy Aging Research on Depression for Younger Women
Actual Study Start Date : October 2, 2019
Estimated Primary Completion Date : June 2, 2021
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Endotoxin
Endotoxin 0.8 ng/kg body weight; 1 infusion
Biological: Endotoxin
Endotoxin

Placebo Comparator: Placebo
same volume of 0.9% saline
Biological: Placebo
Placebo




Primary Outcome Measures :
  1. Non-social (monetary) reward response (reward motivation, learning, sensitivity) [ Time Frame: Baseline and post-injection (approximately 2 hrs) ]
    Motivation for monetary reward is assessed with a 10-minute version of the Effort Expenditure for Rewards Task (EEfRT); change in the amount of hard trials chosen from baseline to post-injection is the outcome measure. Implicit reward learning and sensitivity to monetary reward is assessed with the probabilistic reward task (PRT); change in the magnitude of response bias from baseline to post-injection is the outcome measure.

  2. General social reward response (reward sensitivity and motivation) [ Time Frame: Baseline and post-injection (approximately 2 hrs) ]
    Sensitivity to general social reward cues (i.e., response to positive emotional faces) assessed as positive attentional bias with an emotional dot probe task and positive emotion detection with a face morphing task. Outcomes are change from baseline to post-injection in attentional bias (via reaction time) and identification (via reaction time and accuracy) of positive faces. Motivation for general social reward is assessed via self-report; participants rate their desire to engage in 3 different activities, one of which is social, on a 1 (not at all) to 10 (extremely) Likert scale.; change in desire for the social activity from baseline to post-injection is the outcome variable.


Secondary Outcome Measures :
  1. Close social reward response [ Time Frame: Post-injection (approximately 2 hrs) ]
    Participants spend 5 minutes talking about a "close other" to a research assistant trained in reflective listening and provide ratings of current negative and positive emotion on visual analogue scales (0=not at all; 100=extremely) using items from the Profile of Mood States. Outcome variables are change in self-report positive emotion from pre to post-discussion, and percentage of positive and negative emotional words used during the discussion (scored with Linguistic Inquiry and Word Count Software).

  2. Anticipatory and Consummatory Daily Reward Response [ Time Frame: 14 days (7 days pre-injection; 7 days post-injection). ]
    Participants indicate the extent to which they enjoyed 10 activities (social, non-social, close social) on a 0-100 visual analogue scale (0= not at all; 100=extremely) at five random times during the day; change in enjoyment in each of the domains from pre to post-experimental session is the outcome for consummatory reward. From the same list of activities, participants then rate how much they are currently looking forward to each activity on the same analogue scale (0= not at all; 100=extremely); change from pre to post-experimental session is the outcome for anticipatory reward.

  3. Dopaminergic activity [ Time Frame: Baseline and post-injection (approximately 2 hrs) ]
    Count of eye blinks (resting eye blink rate; EBR) over a five minute period; the outcome is change in EBR from pre to post-injection.

  4. Depressed Mood Subscale of the Profile of Mood States (POMS) [ Time Frame: 12 hours ]
    The Depressed Mood Subscale of the POMS is a self-reported assessment of depressed mood in which subjects rate severity of depressed mood using a visual analog scale from 1 to 5 (5 being most severe). Each timepoint is scored and analyses examine the temporal profile of change with assessment every hour


Other Outcome Measures:
  1. Positive and negative emotion regulation capacity [ Time Frame: post-injection (approximately 3 hrs) ]
    Participants complete a 30 minute standardized emotion regulation task that includes two phases: a reactivity phase and a regulation phase, and assesses the ability to up-regulate positive emotional response to standardized images, and down-regulate negative emotional response to standardized images, both using instructed reappraisal strategies. The dependent variable is the degree to which self-reported emotion changes when reacting to versus reappraising emotion stimuli. Participants rate how negative they feel (1=not at all; 5 = extremely) and how positive they feel (1=not at all; 5 = extremely).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants will be required to be in good general health (as evaluated during the phone and in-person baseline session)
  • Participants will be biologically female and premenopausal (as evaluated by self report).
  • Participants will 25-44 years of age.

Exclusion Criteria:

  • Presence of chronic mental or physical illness
  • History of allergies, autoimmune, liver, or other severe chronic diseases,
  • Current and regular use of prescription medications such as steroids, non-steroid anti-inflammatory drugs, aspirin, immune modifying drugs, opioid analgesics, statins, antihypertensive drugs, anti-arrhythmic drugs, and antidepressant medications (none in the last 6 months).
  • Nightshift work or time zone shifts (> 3hrs) within the previous 6 weeks
  • Previous history of fainting during blood draws.
  • Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders;
  • Presence of comorbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders;
  • Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk;
  • Presence of chronic infection, which may elevate proinflammatory cytokines;
  • Presence of an acute infectious illness in the two weeks prior to an experimental session.
  • Current Axis I psychiatric disorders as determined by the Research Version of the Structured Clinical Interview including a current major depressive disorder and substance dependence
  • Lifetime history of suicide attempt or inpatient psychiatric admission.
  • Current history of sleep apnea or nocturnal myoclonus; Phase-shift disorder, which will be identified by the Structured Clinical Interview and the Duke Structured Interview for Sleep Disorders
  • Current smoking or excessive caffeine use (>600 mg/day) because of the known effects on proinflammatory cytokine levels;
  • Evidence of recreational drug use from urine test.
  • Body mass index > 35 because of the effects of obesity on proinflammatory cytokine activity
  • Any clinically significant abnormality on screening laboratory tests
  • Clinically significant abnormalities in electrocardiogram

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03848715


Contacts
Layout table for location contacts
Contact: Chloe C Boyle, PhD 310 825 8788 ccboyle@ucla.edu

Locations
Layout table for location information
United States, California
Norman Cousins Center for Psychoneuroimmunology, University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Chloe Boyle, PhD    310-825-8788      
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Chloe C Boyle, PhD University of California, Los Angeles
Principal Investigator: Michael R Irwin, MD University of California, Los Angeles
  Study Documents (Full-Text)

Documents provided by Chloe Boyle, PhD, University of California, Los Angeles:
Layout table for additonal information
Responsible Party: Chloe Boyle, PhD, Postdoctoral Fellow, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT03848715    
Other Study ID Numbers: 16-000583-AM-00016
First Posted: February 21, 2019    Key Record Dates
Last Update Posted: November 3, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anhedonia
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases